Monoclonal antibody | |
---|---|
Type | Whole antibody |
Target | CD40 ligand |
Clinical data | |
AHFS/Drugs.com | Monograph |
License data |
|
Legal status | |
Legal status |
|
Identifiers | |
PubChem SID | |
ChemSpider |
|
KEGG |
Frexalimab (SAR441344) is a second-generation monoclonal antibody that inhibits CD40 ligand. It is in development by Sanofi for the treatment of relapsing multiple sclerosis. [1] [2] [3] [4] [5] [6]